Nano Dimension appoints Nadav Kidron to Board; Infinite Epigenetics term sheet lapses
Nano Dimension appointed Nadav Kidron as an independent director on August 16, 2026, effective immediately, with seats on the Audit and Compensation Committees. In a separate Regulation FD disclosure, the company said the 30-day exclusivity period under a non-binding term sheet with Infinite Epigenetics expired on July 15, 2026, and no definitive agreement has been reached.
Key points
- Nadav Kidron appointed to the Board as a Class II director effective August 16, 2026, serving until the 2026 annual meeting
- Kidron to serve on the Audit Committee and Compensation Committee; Board determined he is independent under Nasdaq rules
- Exclusivity under the non-binding term sheet with Infinite Epigenetics, Inc. expired July 15, 2026
- As of the filing date, the parties have not agreed on terms of a definitive agreement
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 18, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.